Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study

European Journal of Cancer

Volumn 50, Issue 1, 2014, Pages 170-177

  Di Giannatale, Angela ^a   Dias Gastellier, Nathalie ^a   Devos, Annick ^b   Mc Hugh, Kieran ^c   Boubaker, Ariane ^d   Courbon, Frederic ^e   Verschuur, Arnaud ^f   Ducassoul, Stéphane ^g   Malekzadeh, Katty ^a   Casanova, Michela ^h   Amoroso, Loredana ⁱ   Chastagner, Pascal ^j   Zwaan, Christian M ^b   Munzer, Caroline ^k   Aerts, Isabelle ⁿ   Landman Parker, Judith ^l   Riccardi, Riccardo ^m   Le Deley, Marie Cecile ^a   Geoerger, Birgit ^a   Rubie, Hervé ^k  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f TIMONE HOSPITAL   (France)

^g HÔPITAL PELLEGRIN   (France)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ G GASLINI INSTITUTE   (Italy)

^j CHU NANCY BRABOIS   (France)

^k HÔPITAL DES ENFANTS   (France)

^l INSTITUT CURIE   (France)

^m ARMAND TROUSSEAU HOSPITAL   (France)

ⁿ CATHOLIC UNIVERSITY   (Italy)

more..

Author keywords

Neuroblastoma; Paediatrics; Phase II; Temozolomide; Topotecan

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER CYTODIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE; OVERALL SURVIVAL; PARENT; PATIENT HISTORY OF CHEMOTHERAPY; PATIENT HISTORY OF RADIOTHERAPY; PATIENT HISTORY OF SURGERY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE;

NEUROBLASTOMA; PAEDIATRICS; PHASE II; TEMOZOLOMIDE; TOPOTECAN;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEMALE; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; RECURRENCE; TOPOTECAN; YOUNG ADULT;

EID: 84891624988     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.08.012     Document Type: Article

References (38)

1. J.M. Maris, M.D. Hogarty, and R. Bagatell et al. Neuroblastoma Lancet 369 2007 2106 2120
2. W.B. London, V. Castel, and T. Monclair et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project J Clin Oncol 29 2011 3286 3292
3. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones Biochem Pharmacol 36 1987 457 462
4. D.S. Middlemas, C.F. Stewart, and M.N. Kirstein et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models Clin Cancer Res 6 2000 998 1007
5. N. Mutter, and R. Stupp Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 6 2006 1187 1204
6. E.J. Estlin, L. Lashford, and S. Ablett et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group Br J Cancer 78 1998 652 661
7. H.S. Friedman, T. Kerby, and H. Calvert et al. Temozolomide and treatment of malignant glioma Clin Cancer Res 6 2000 2585 2597
8. H.S. Nicholson, M. Krailo, and M.M. Ames et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group J Clin Oncol 16 1998 3037 3043
9. L. De Sio, G.M. Milano, and A. Castellano et al. Temozolomide in resistant or relapsed pediatric solid tumors Pediatr Blood Cancer 47 2006 30 36
10. H. Rubie, J. Chisholm, and A.S. Defachelles et al. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study J Clin Oncol 24 2006 5259 5264
11. H. Carol, P.J. Houghton, and C.L. Morton et al. Initial testing of topotecan by the pediatric preclinical testing program Pediatr Blood Cancer 54 2010 707 715
12. G. Vassal, C. Pondarré, and C. Cappelli et al. DNA-topoisomerase I, a new target for the treatment of neuroblastome Eur J Cancer 33 1997 2011 2015
13. S.M. Blaney, M.N. Needle, and A. Gillespie et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study Clin Cancer Res 4 1998 357 360
14. N.C. Daw, V.M. Santana, and L.C. Iacono et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors J Clin Oncol 22 2004 829 837
15. A. Längler, A. Christaras, and K. Abshagen et al. Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood-a phase-II-study Klin Padiatr 214 2002 153 156
16. R. Nitschke, J. Parkhurst, and J. Sullivan et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study J Pediatr Hematol Oncol 20 1998 315 318
17. C.B. Pratt, C. Stewart, and V.M. Santana et al. Phase I study of topotecan for pediatric patients with malignant solid tumors J Clin Oncol 12 1994 539 543
18. D.G. Tubergen, C.F. Stewart, and C.B. Pratt et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study J Pediatr Hematol Oncol 18 1996 352 361
19. V.M. Santana, W.L. Furman, and C.A. Billups et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach J Clin Oncol 23 2005 4039 4047
20. 6-methylguanine Cancer Res 61 2001 53 58
21. 6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models Clin Cancer Res 6 2000 4110 4118
22. H. Rubie, B. Geoerger, and D. Frappaz et al. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours Eur J Cancer 46 2010 2763 2770
23. G.M. Brodeur, J. Pritchard, and F. Berthold et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment J Clin Oncol 11 1993 1466 1477
24. 123I-metaiodobenzylguanidine scans in neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) Task Force J Clin Oncol 102 2010 1319 1326
25. P.J. Houghton, P.J. Cheshire, and J.C. Hallman et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1- piperidino)-carbonyloxycampto thecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin Cancer Res 53 1993 2823 2829
26. W.R. Waud, L.V. Rubinstein, and S. Kalyandrug et al. In vivo combination chemotherapy evaluations of topotecan with cisplatin and temozolomide Proc Am Assoc Cancer Res 37 1996 292
27. B.H. Kushner, K. Kramer, and S. Modak et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma J Clin Oncol 24 2006 5271 5276
28. R. Bagatell, W.B. London, and L.M. Wagner et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study J Clin Oncol 29 2011 208 213
29. L.M. Wagner, N. McAllister, and R.E. Goldsby et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma Pediatr Blood Cancer 48 2007 132 139
30. D.A. Casey, L.H. Wexler, and M.S. Merchant et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience Pediatr Blood Cancer 53 2009 1029 1034
31. G. Vassal, F. Giammarile, and M. Brooks et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG) Eur J Cancer 44 2008 2453 2460
32. L.R. Bomgaars, M. Bernstein, and M. Krailo et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study J Clin Oncol 25 2007 4622 4627
33. B.H. Kushner, K. Kramer, and S. Modak et al. High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan Pediatr Blood Cancer 56 2011 403 408
34. B.H. Kushner, K. Kramer, and S. Modak et al. High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma Eur J Cancer 47 2011 84 89
35. A. Garaventa, R. Luksch, and S. Biasotti et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma Cancer 98 2003 2488 2494
36. J.R. Park, J.R. Scott, and C.F. Stewart et al. Pilot induction regimen incorporating phamacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group Study J Clin Oncol 29 2011 4351 4357
37. T. Simon, A. Längler, and U. Harnischmacher et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial J Cancer Res Clin Oncol 133 2007 653 661
38. W.B. London, C.N. Frantz, and L.A. Campbell et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study J Clin Oncol 28 2010 3808 3815